Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hong-Hu Zhu

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Leukemia Research|December 3, 2014
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese centerYa-Zhen Qin, Hong-Hu Zhu, Qian Jiang, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|February 7, 2018
High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving ChemotherapyYa-Zhen Qin, Ting Zhao, Hong-Hu Zhu, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi|June 28, 2006
[Application of CD123 in detection of minimal residual disease in acute promyelocytic leukemia]Ya-Zhe Wang, Yan Chang, Hong-Hu Zhu, et al.
Chinese Medical Journal|September 29, 2009
Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemiaXiao-hui Zhang, Yu Hu, Li Bao, et al.
Hematological Oncology|February 28, 2024
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysisRong Wang, Yi Zhang, Jie Chang, et al.
British Journal of Haematology|March 25, 2021
Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemiaHuanping Wang, Yile Zhou, Xin Huang, et al.
Frontiers in Oncology|December 16, 2020
Hypertriglyceridemia in Newly Diagnosed Acute Promyelocytic LeukemiaJianai Sun, Yinjun Lou, Jingjing Zhu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 28, 2008
[PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease]Ya-zhen Qin, Jin-lan Li, Hong-hu Zhu, et al.
Cell Communication and Signaling : CCS|April 4, 2025
Machine learning-based in-silico analysis identifies signatures of lysyl oxidases for prognostic and therapeutic response prediction in cancerQingyu Xu, Ling Ma, Alexander Streuer, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi|December 28, 2013
[Immunophenotypic and clinical characteristic analysis of NPM1 mutated acute myeloid leukemia with a normal karyotype]Yan-Rong Liu, Yue-Yun Lai, Yan Chang, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Leukemia Research|December 3, 2014
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese centerYa-Zhen Qin, Hong-Hu Zhu, Qian Jiang, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|February 7, 2018
High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving ChemotherapyYa-Zhen Qin, Ting Zhao, Hong-Hu Zhu, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi|June 28, 2006
[Application of CD123 in detection of minimal residual disease in acute promyelocytic leukemia]Ya-Zhe Wang, Yan Chang, Hong-Hu Zhu, et al.
Chinese Medical Journal|September 29, 2009
Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemiaXiao-hui Zhang, Yu Hu, Li Bao, et al.
Hematological Oncology|February 28, 2024
Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysisRong Wang, Yi Zhang, Jie Chang, et al.
British Journal of Haematology|March 25, 2021
Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemiaHuanping Wang, Yile Zhou, Xin Huang, et al.
Frontiers in Oncology|December 16, 2020
Hypertriglyceridemia in Newly Diagnosed Acute Promyelocytic LeukemiaJianai Sun, Yinjun Lou, Jingjing Zhu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|November 28, 2008
[PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease]Ya-zhen Qin, Jin-lan Li, Hong-hu Zhu, et al.
Cell Communication and Signaling : CCS|April 4, 2025
Machine learning-based in-silico analysis identifies signatures of lysyl oxidases for prognostic and therapeutic response prediction in cancerQingyu Xu, Ling Ma, Alexander Streuer, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi|December 28, 2013
[Immunophenotypic and clinical characteristic analysis of NPM1 mutated acute myeloid leukemia with a normal karyotype]Yan-Rong Liu, Yue-Yun Lai, Yan Chang, et al.
Pageof 12